Daxor Corporation (NASDAQ:DXR) Stock Short Interest Report for October

Daxor Corporation (NASDAQ:DXR) was the target of a large decline in short interest in October. As of October 15th, there was short interest totaling 3,374 shares, a decline of 51.5% from the September 30th total of 6,959 shares. Currently, 0.1% of the shares of the stock are sold short. Based on an average daily trading volume, of 12,606 shares, the days-to-cover ratio is currently 0.3 days.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Daxor in a report on Monday, September 21st. One equities research analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy”.

Institutional Investors Weigh In On Daxor

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Susquehanna International Group LLP raised its position in Daxor by 97.7% in the 2nd quarter. Susquehanna International Group LLP now owns 27,131 shares of the company’s stock valued at $275,000 after purchasing an additional 13,411 shares during the last quarter. Aristides Capital LLC bought a new stake in shares of Daxor during the first quarter worth $403,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management bought a new stake in shares of Daxor during the first quarter worth $245,000. Finally, Crescent Grove Advisors LLC bought a new stake in shares of Daxor during the first quarter worth $104,000. 1.34% of the stock is owned by institutional investors and hedge funds.

Daxor Stock Performance

Shares of NASDAQ DXR traded up $0.28 during mid-day trading on Friday, hitting $9.20. 28,009 shares of the stock were exchanged, compared to its average volume of 11,221. Daxor has a twelve month low of $8.40 and a twelve month high of $14.76. The stock’s fifty day simple moving average is $10.40 and its two-hundred day simple moving average is $10.76.

Daxor Company Profile

Daxor Corporation (NASDAQ: DXR) is a medical device and biotechnology company focused on blood-volume measurement and related diagnostic applications. Its primary product is the BVA-100 Blood Volume Analyzer, a system designed to measure a patient’s total blood volume, plasma volume, red blood cell volume and hematocrit.

The BVA-100 uses a blood sample and an iodine-131-labeled albumin tracer to provide quantitative blood-volume measurements. The technology is intended to support clinical assessment and management in areas including heart failure, critical care, kidney disease, blood disorders and perioperative care, where accurate information about a patient’s fluid and blood-volume status can assist treatment decisions.

Daxor markets its technology primarily to hospitals and other healthcare providers and also supports clinical research involving blood-volume measurement.